Critical Analysis: Pulse Biosciences (NASDAQ:PLSE) and Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS)

Pulse Biosciences (NASDAQ:PLSE) and Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Institutional and Insider Ownership

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 12.4% of Senseonics Holdings, Inc. Common Stock shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 4.7% of Senseonics Holdings, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Pulse Biosciences has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Senseonics Holdings, Inc. Common Stock has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pulse Biosciences and Senseonics Holdings, Inc. Common Stock”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350,000.00	10,079.90	-$72.78 million	($1.18)	-42.23
Senseonics Holdings, Inc. Common Stock	$35.26 million	11.81	-$69.11 million	($2.23)	-4.47

Senseonics Holdings, Inc. Common Stock has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Senseonics Holdings, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Pulse Biosciences and Senseonics Holdings, Inc. Common Stock, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	5	1	2.86
Senseonics Holdings, Inc. Common Stock	1	1	4	0	2.50

Pulse Biosciences presently has a consensus target price of $50.20, indicating a potential upside of 0.74%. Senseonics Holdings, Inc. Common Stock has a consensus target price of $17.20, indicating a potential upside of 72.69%. Given Senseonics Holdings, Inc. Common Stock’s higher probable upside, analysts plainly believe Senseonics Holdings, Inc. Common Stock is more favorable than Pulse Biosciences.

Profitability

This table compares Pulse Biosciences and Senseonics Holdings, Inc. Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Senseonics Holdings, Inc. Common Stock	-225.09%	-165.80%	-80.14%

Summary

Pulse Biosciences beats Senseonics Holdings, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company’s products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.